First study demonstrating Decipher Prostate test can inform treatment decisions in nmCRPC SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 14, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced new data demonstrating the prognostic utility of the company’s Decipher ® Prostate genomic
First Molecular Subtyping Test to Gain Medicare Coverage to Inform Treatment for Individuals With Bladder Cancer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 4, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Medicare Administrative Contractors Palmetto GBA, WPS and CGS
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 2, 2021-- Details of the Raymond James Human Health Innovation Conference have been corrected. The updated release reads: VERACYTE TO PRESENT AT UPCOMING INVESTOR CONFERENCES Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company,
Fueling growth by enabling IVD test development and manufacturing, deepening scientific capabilities and expanding cancer diagnostics scope to 8 of the 10 top cancers in the U.S. Investor conference call and webcast today at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 26, 2021-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson , chairman, chief executive officer and incoming executive chairman, and Marc Stapley , incoming chief executive officer, are
Study findings to be presented June 4 at ASCO Annual Meeting SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 26, 2021-- Veracyte, Inc ., (Nasdaq: VCYT) announced today new data that show the company’s Afirma Xpression Atlas (XA) can identify clinically relevant gene fusions in thyroid nodule
- VANDAAM study findings confirm test predicts aggressive prostate cancer in African American men - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 25, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced new data from two studies that further demonstrate the Decipher ® Prostate Genomic
Company to hold webcast to discuss findings on Thursday, May 20 , at 10:00 a.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 19, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced pivotal clinical validation data showing that the company’s noninvasive nasal swab test can significantly
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 18, 2021-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson , chairman, chief executive officer and incoming executive chairman, and Marc Stapley , incoming chief executive officer, are
New findings presented at ATS 2021 Conference also suggest novel test can be successfully enabled on nCounter Analysis System to support international expansion SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 14, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced that data reinforcing the
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
